Zydus Lifesciences posts 6% revenue growth in Q1 FY26, Net profit rises to Rs 14,668 Million

New Delhi: Zydus Lifesciences Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2025, reporting a revenue from operations of Rs 65,737 million, a 6% year-on-year growth. Research and development investments stood at Rs 4,856 million, representing 7.4% of revenues.

EBITDA was Rs 20,885 million, remaining flat compared to the previous year, with a margin of 31.8%. Net profit rose 3% year-on-year to ₹14,668 million, while organic capex for the quarter was Rs 4,020 million.

The India geography business, contributing 37% to consolidated revenues, generated Rs 23,744 million, a 6% rise from the previous year. The formulations segment posted Rs 15,195 million, growing 8% year-on-year, driven by robust performance in chronic therapies such as cardiology, respiratory, anti-infectives, pain management, and oncology, where the company retained its leadership position. The consumer wellness business recorded Rs 8,549 million, a 2% increase, with strong double-digit growth in non-seasonal brands and a rising share of organized trade and e-commerce sales.

The US formulations business contributed 49% of revenues at Rs 31,817 million, growing 3% year-on-year, with three new product launches, three ANDA filings, and six product approvals. The international markets formulations segment rose sharply by 37% to Rs 7,265 million, while the API business grew 11% to Rs 1,575 million. Revenues from alliances and others declined 28% to ₹269 million. The company’s API facilities at Ankleshwar and Dabhasa received Establishment Inspection Reports from the USFDA.

On the innovation front, Zydus initiated Phase II(b) clinical trials of Usnoflast, a novel NLRP3 inflammasome inhibitor for ALS, which also received USFDA Fast Track designation and holds Orphan Drug Designation. Its biotech R&D received marketing authorization for Rituximab and Aflibercept biosimilars and Phase III trial approval for a second antibody drug conjugate. In vaccines, the company completed Phase II trials of a Hepatitis E vaccine and began Phase IV trials of its rabies vaccine.

Strategic moves included entering the global biologics CDMO space with the planned acquisition of Agenus Inc.’s US-based manufacturing facilities and completing a stake acquisition in France’s Amplitude Surgical SA, a leader in lower-limb orthopedic technologies. The company remains optimistic about achieving its FY26 goals and sees upcoming innovations as key to sustainable growth.